<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530970</url>
  </required_header>
  <id_info>
    <org_study_id>14-PR-1110</org_study_id>
    <nct_id>NCT02530970</nct_id>
  </id_info>
  <brief_title>A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope</brief_title>
  <acronym>SECURE</acronym>
  <official_title>A Post Market Observational Study to Obtain Additional Information on the Use of Cormatrix® Cangaroo ECM® Envelope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorMatrix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorMatrix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the SECURE Study is to actively gather additional information on the use of
      the CorMatrix® CanGaroo ECM® Envelope in a post market observational study.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. The proportion of subjects with CorMatrix CanGaroo ECM related adverse events.</measure>
    <time_frame>Participants will be followed for an expected average of 3 months.</time_frame>
    <description>Device related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. The incidence of major pocket infection.</measure>
    <time_frame>Participants will be followed for an expected average of 3 months.</time_frame>
    <description>Major Infection</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cardiovascular Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have received CorMatrix® CanGaroo ECM® Envelope for an implantable electronic
        device placement.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have received CorMatrix® CanGaroo ECM® Envelope for an implantable
             electronic device placement.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Green</last_name>
    <role>Study Director</role>
    <affiliation>CorMatrix Cardiovascular, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>August 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
